CD19 and neoplasm: Together, these results demonstrate that the tumor microenvironment itself harbors phenotypically distinct immune cell populations, with 4T1 tumors promoting a RANKL+ CD3+ CD4+ T cell phenotype and 67NR tumors sustaining OPG+ CD19+ B cells.